Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N -phenyl-aminobenzoates and their structure-activity relationships

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 2311-2323

  Adeniji, Adegoke O ^a   Twenter, Barry M ^b   Byrns, Michael C ^a   Jin, Yi ^a   Chen, Mo ^a   Winkler, Jeffrey D ^b   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 METHOXYPHENYL)AMINO]BENZOIC ACID; 3 [[3,5 BIS(TRIFLUOROMETHYL)PHENYL]AMINO]BENZOIC ACID; 4 [(3 NITROPHENYL)AMINO]BENZOIC ACID; 4 METHOXY 2 [(3 NITROPHENYL)AMINO]BENZOIC ACID; 5 ACETYL 2 [[4 (TRIFLUOROMETHYL)PHENYL]AMINO]BENZOIC ACID; AMINE; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLUFENAMIC ACID; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTRON; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FENAMATES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; ISOENZYMES; MALE; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 84863230589     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201547v     Document Type: Article

References (52)

1. Altekruse, S. F.; Kosary, C. L.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Eisner, M. P.; Lewis, D. R.; Cronin, K.; Chen, H. S.; Feuer, E. J.; Stinchcomb, D. G.; Edwards, B. K., Eds.; SEER Cancer Statistics Review, 1975-2007; National Cancer Institute: Bethesda, MD, 2010; http://seer.cancer.gov/csr/1975-2007/ based on November 2009 SEER data submission, posted to the SEER web site.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010 CA Cancer J. Clin. 2010, 60, 277-300
3. Knudsen, K. E.; Penning, T. M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 2010, 21, 315-324
4. Knudsen, K. E.; Scher, H. I. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clin. Cancer Res. 2009, 15, 4792-4798
5. Locke, J. A.; Guns, E. S.; Lubik, A. A.; Adomat, H. H.; Hendy, S. C.; Wood, C. A.; Ettinger, S. L.; Gleave, M. E.; Nelson, C. C. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res. 2008, 68, 6407-6415
6. Attard, G.; Reid, A. H.; A'Hern, R.; Parker, C.; Oommen, N. B.; Folkerd, E.; Messiou, C.; Molife, L. R.; Maier, G.; Thompson, E.; Olmos, D.; Sinha, R.; Lee, G.; Dowsett, M.; Kaye, S. B.; Dearnaley, D.; Kheoh, T.; Molina, A.; de Bono, J. S. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 2009, 27, 3742-3748
7. O'Donnell, A.; Judson, I.; Dowsett, M.; Raynaud, F.; Dearnaley, D.; Mason, M.; Harland, S.; Robbins, A.; Halbert, G.; Nutley, B.; Jarman, M. Hormonal impact of the 17α-hydroxylase/CYP(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer Br. J. Cancer 2004, 90, 2317-2325
8. Reid, A. H.; Attard, G.; Danila, D. C.; Oommen, N. B.; Olmos, D.; Fong, P. C.; Molife, L. R.; Hunt, J.; Messiou, C.; Parker, C.; Dearnaley, D.; Swennenhuis, J. F.; Terstappen, L. W.; Lee, G.; Kheoh, T.; Molina, A.; Ryan, C. J.; Small, E.; Scher, H. I.; de Bono, J. S. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J. Clin. Oncol. 2010, 28, 1489-1495
9. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324, 787-790
10. Jung, M. E.; Ouk, S.; Yoo, D.; Sawyers, C. L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 2010, 53, 2779-2796
11. Stanbrough, M.; Bubley, G. J.; Ross, K.; Golub, T. R.; Rubin, M. A.; Penning, T. M.; Febbo, P. G.; Balk, S. P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 2006, 66, 2815-2825
12. Montgomery, R. B.; Mostaghel, E. A.; Vessella, R.; Hess, D. L.; Kalhorn, T. F.; Higano, C. S.; True, L. D.; Nelson, P. S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 2008, 68, 4447-4454
13. Lin, H. K.; Jez, J. M.; Schlegel, B. P.; Peehl, D. M.; Pachter, J. A.; Penning, T. M. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution Mol. Endocrinol. 1997, 11, 1971-1984
14. Penning, T. M.; Burczynski, M. E.; Jez, J. M.; Hung, C. F.; Lin, H. K.; Ma, H.; Moore, M.; Palackal, N.; Ratnam, K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 2000, 351, 67-77
15. Chang, K. H.; Li, R.; Papari-Zareei, M.; Watumull, L.; Zhao, Y. D.; Auchus, R. J.; Sharifi, N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 13728-13733
16. Burczynski, M. E.; Harvey, R. G.; Penning, T. M. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans -7,8-dihydroxy-7,8-dihydrobenzo[ a ]pyrene to the activated o -quinone metabolite benzo[ a ]pyrene-7,8-dione Biochemistry 1998, 37, 6781-6790
17. Steckelbroeck, S.; Jin, Y.; Gopishetty, S.; Oyesanmi, B.; Penning, T. M. Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action J. Biol. Chem. 2004, 279, 10784-10795
18. Rizner, T. L.; Lin, H. K.; Peehl, D. M.; Steckelbroeck, S.; Bauman, D. R.; Penning, T. M. Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells Endocrinology 2003, 144, 2922-2932
19. Guerini, V.; Sau, D.; Scaccianoce, E.; Rusmini, P.; Ciana, P.; Maggi, A.; Martini, P. G.; Katzenellenbogen, B. S.; Martini, L.; Motta, M.; Poletti, A. The androgen derivative 5α-androstane-3β,17β-diol inhibits prostate cancer cell migration through activation of the estrogen receptor β subtype Cancer Res. 2005, 65, 5445-5453
20. Penning, T. M.; Talalay, P. Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4504-4508
21. Matsuura, K.; Shiraishi, H.; Hara, A.; Sato, K.; Deyashiki, Y.; Ninomiya, M.; Sakai, S. Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity J. Biochem. 1998, 124, 940-946
22. Pawlowski, J.; Huizinga, M.; Penning, T. M. Isolation and partial characterization of a full-length cDNA clone for 3α-hydroxysteroid dehydrogenase: a potential target enzyme for nonsteroidal anti-inflammatory drugs Agents Actions 1991, 34, 289-293
23. Bauman, D. R.; Rudnick, S. I.; Szewczuk, L. M.; Jin, Y.; Gopishetty, S.; Penning, T. M. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Mol. Pharmacol. 2005, 67, 60-68
24. Byrns, M. C.; Steckelbroeck, S.; Penning, T. M. An indomethacin analogue, N -(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 2008, 75, 484-493
25. Desmond, J. C.; Mountford, J. C.; Drayson, M. T.; Walker, E. A.; Hewison, M.; Ride, J. P.; Luong, Q. T.; Hayden, R. E.; Vanin, E. F.; Bunce, C. M. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs Cancer Res. 2003, 63, 505-512
26. Lombardino, J. G. Nonsteroidal Antiinflammatory Drugs; Wiley Interscience: New York, 1985.
27. Scherrer, A. R. Antiinflammatory Agents: Chemistry and Pharmacology; Academic Press: New York, 1974.
28. 2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations Biochemistry 2001, 40, 5172-5180
29. Csuk, R.; Barthel, A.; Raschke, C. Convenient access to substituted acridines by a Buchwald-Hartwig amination Tetrahedron 2004, 60, 5737-5750
30. Hamann, B. C.; Hartwig, J. F. Systematic variation of bidentate ligands used in aryl halide amination. Unexpected effects of steric, electronic, and geometric perturbations J. Am. Chem. Soc. 1998, 120, 3694-3703
31. Old, D. W.; Wolfe, J. P.; Buchwald, S. L. A highly active catalyst for palladium-catalyzed cross-coupling reactions: room-temperature Suzuki couplings and amination of unactivated aryl chlorides J. Am. Chem. Soc. 1998, 120, 9722-9723
32. +) and ursodeoxycholate Biochemistry 2001, 40, 10161-10168
33. Endo, S.; Matsunaga, T.; Soda, M.; Tajima, K.; Zhao, H. T.; El-Kabbani, O.; Hara, A. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N -phenylanthranilic acids and glycyrrhetic acid Biol. Pharm. Bull. 2010, 33, 886-890
34. Barnett, J.; Chow, J.; Ives, D.; Chiou, M.; Mackenzie, R.; Osen, E.; Nguyen, B.; Tsing, S.; Bach, C.; Freire, J.; Chan, H.; Sigal, E.; Ramesha, C. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system Biochim. Biophys. Acta 1994, 1209, 130-139
35. Lovering, A. L.; Ride, J. P.; Bunce, C. M.; Desmond, J. C.; Cummings, S. M.; White, S. A. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin Cancer Res. 2004, 64, 1802-1810
36. Byrns, M. C.; Jin, Y.; Penning, T. M. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 2010, 125, 95-104
37. Penning, T. M.; Ma, H.; Jez, J. M. Engineering steroid hormone specificity into aldo-keto reductases Chem.-Biol. Interact. 2001, 130-132, 659-671
38. Jin, Y. Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids Chem. Biol. Interact. 2011, 191, 234-238
39. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications Pharmacol. Rev. 1998, 50, 21-33
40. Crosas, B.; Hyndman, D. J.; Gallego, O.; Martras, S.; Pares, X.; Flynn, T. G.; Farres, J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism Biochem. J. 2003, 373, 973-979
41. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; Fetzer, L.; Scherer, C.; Muller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2008, 51, 2158-2169
42. Marchais-Oberwinkler, S.; Frotscher, M.; Ziegler, E.; Werth, R.; Kruchten, P.; Messinger, J.; Thole, H.; Hartmann, R. W. Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors Mol. Cell. Endocrinol. 2009, 301, 205-211
43. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; Bhoga, U.; Bey, E.; Muller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): design, synthesis, biological evaluation, and pharmacokinetics J. Med. Chem. 2008, 51, 4685-4698
44. Penning, T. M.; Burczynski, M. E.; Jez, J. M.; Lin, H. K.; Ma, H.; Moore, M.; Ratnam, K.; Palackal, N. Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Mol. Cell. Endocrinol. 2001, 171, 137-149
45. Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17β-HSD2 inhibitors for the treatment of osteoporosis: identification of a promising scaffold Bioorg. Med. Chem. 2011, 19, 807-815
46. Wetzel, M.; Marchais-Oberwinkler, S.; Perspicace, E.; Moller, G.; Adamski, J.; Hartmann, R. W. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β- hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors J. Med. Chem. 2011, 54, 7547-7557
47. Schuster, D.; Kowalik, D.; Kirchmair, J.; Laggner, C.; Markt, P.; Aebischer-Gumy, C.; Strohle, F.; Moller, G.; Wolber, G.; Wilckens, T.; Langer, T.; Odermatt, A.; Adamski, J. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening J. Steroid Biochem. Mol. Biol. 2011, 125, 148-161
48. Quinn, A. M.; Harvey, R. G.; Penning, T. M. Oxidation of PAH trans -dihydrodiols by human aldo-keto reductase AKR1B10 Chem. Res. Toxicol. 2008, 21, 2207-2215
49. George, H. J.; Van Dyk, D. E.; Straney, R. A.; Trzaskos, J. M.; Copeland, R. A. Expression purification and characterization of recombinant human inducible prostaglandin G/H synthase from baculovirus-infected insect cells Protein Expression Purif. 1996, 7, 19-26
50. Smith, T.; Leipprandt, J.; DeWitt, D. Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2 Arch. Biochem. Biophys. 2000, 375, 195-200
51. Gierse, J. K.; Koboldt, C. M.; Walker, M. C.; Seibert, K.; Isakson, P. C. Kinetic basis for selective inhibition of cyclo-oxygenases Biochem. J. 1999, 339 (Pt 3) 607-614
52. Byrns, M. C.; Mindnich, R.; Duan, L.; Penning, T. M. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride J. Steroid Biochem. Mol. Biol. 2012, 10.1016/j.jsbmb.2011.12.012